Impact of Pre-pregnancy Micronutrient Supplementation on Maternal and Child Outcomes

September 30, 2026 updated by: Usha Ramakrishnan, Emory University

Impact of Pre-Pregnancy Micronutrient Supplementation on Maternal and Child Outcomes

The study evaluates the efficacy of providing weekly iron-folate (IFA) supplements or Multiple Micronutrient (MM) supplements before pregnancy in increasing birth weight and duration of gestation as well as maternal and infant iron status.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Low birth weight and anemia remain intractable problems in many developing countries despite considerable efforts to address them. Intervening with just prenatal iron-folate (IFA) supplements may not be the best approach given the substantial demands for iron by maternal and fetal tissues. Therefore, there is an urgent need to evaluate the additional contribution of prepregnancy interventions.

Low birth weight (LBW) and anemia remain public health problems in many developing countries. There is a great deal of evidence in the literature that anemia, primarily due to iron deficiency, has been associated with poor birth outcomes and LBW. The most common interventions is the provision of iron-folate (IFA) supplements during pregnancy. Despite several decades of effort, the success of these interventions in improving anemia and LBW was limited due to: inadequate coverage, high costs and an inability to sustain the programs. Reasons for low effectiveness also include inadequacy of delivery systems, side effects and poor compliance among pregnant women. In addition, intervening with iron-folate (IFA) supplements during pregnancy alone may not be sufficient as many women enter pregnancy with suboptimal iron stores. Weekly pre-pregnancy IFA supplementation (WIFS) has been introduced as a way to reduce the burden of anemia and improve birth outcomes. WIFS has been shown to improve iron status and reduce the burden of anemia in Women of Reproductive Age (WRA) in the short term, but no study has assessed the effects of this intervention on birth outcomes.

The study evaluates the efficacy of providing weekly iron-folate (IFA) supplements or Multiple Micronutrient (MM) supplements before pregnancy in increasing birth weight and duration of gestation as well as maternal and infant iron status. The study will be conducted in Vietnam, a developing country, where anemia and Iron Deficiency (ID) are highly prevalent and will provide valuable scientific evidence that will inform policy. Infants born to women receiving the intervention are followed up to age 10 to 11 to assess periconception nutrition on early adolescent body size, anemic status, cognitive and academic achievement.

Study Type

Interventional

Enrollment (Actual)

5011

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Thái Nguyên
      • Thai Nguyen, Thái Nguyên, Vietnam, 24000
        • Thai Nguyen University of Medicine and Pharmacy

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria for Women:

  • 18-35 years old
  • Currently married
  • Currently living in one of the 10 communes and intends to live in the areas for 24 months following recruitment
  • Plans to have children in the next year
  • Agrees to participate with informed consent

Exclusion Criteria for Women:

  • Currently pregnant
  • Delivered in the previous six months
  • Regularly consumed IFA or MM supplements in the past 2 months
  • Severe anemia (Hb < 7 g/L)
  • History of high risk pregnancy including abruptio placenta, placenta previa, gestational diabetes, pregnancy induced hypertension, coagulation disorders, thrombocytopenia or chronic vascular, renal or systemic disease and drug use
  • Chronic hematological diseases, hereditary defects of red cells or hemoglobin

Inclusion Criteria for Offspring:

  • Child of a female participant of the original study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Multiple Micronutrient - 1

The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Multiple micronutrient groups 1 and 2 receive a supplement that is taken weekly during pre-pregnancy.

There is no current recommendation for weekly MM supplements for WRA. Therefore, the researchers propose a supplement that contains: The same amounts of iron and folic acid as the weekly, pre-natal IFA supplement; An amount of vitamin D based on the Food and Nutrition Board's Recommended Daily Allowances (RDA); UNICEF/WHO/United Nations University (UNU) recommended amounts of remaining nutrients (UNIMMAP recommendations). The supplement is taken weekly during pre-pregnancy and contains:

  • 800 μg Vitamin A
  • 600 IU Vitamin D
  • 10 mg Vitamin E
  • 70 mg Vitamin C
  • 1.4 mg Thiamine
  • 1.4 mg Riboflavin
  • 18 mg Niacin
  • 1.9 mg Vitamin B6
  • 2.6 μg Vitamin B12
  • 2800 μg Folic Acid
  • 60 mg Iron
  • 15 mg Zinc
  • 2 mg Copper
  • 65 μg Selenium
  • 150 μg Iodine
Active Comparator: Iron and Folic Acid - 1

The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Iron and folic acid groups 1 and 2 receive: iron (60mg) and folic acid (2800μg), based on current World Health Organization (WHO) recommendations for WRA.

The doses of weekly and daily iron (60mg) and folic acid (2800μg) are based on current WHO recommendations for WRA.

Placebo Comparator: Folic Acid - 1

The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period.

It is unethical to have a placebo group as FA is universally recommended for WRA to prevent neural tube defects. Therefore, the control group will receive 2800 μg FA once a week during the pre-pregnancy period. This dosage is safe and meets the minimum recommended intake of 400 μg/d for Women of Reproductive Age (WRA). Recent studies have shown that a weekly dose of 2800 μg FA is as effective as a daily dose of 400 μg in improving folic acid and reducing homocysteine levels among WRA.

Experimental: Multiple Micronutrient - 2

The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Multiple micronutrient groups 1 and 2 receive a supplement that is taken weekly during pre-pregnancy.

There is no current recommendation for weekly MM supplements for WRA. Therefore, the researchers propose a supplement that contains: The same amounts of iron and folic acid as the weekly, pre-natal IFA supplement; An amount of vitamin D based on the Food and Nutrition Board's Recommended Daily Allowances (RDA); UNICEF/WHO/United Nations University (UNU) recommended amounts of remaining nutrients (UNIMMAP recommendations). The supplement is taken weekly during pre-pregnancy and contains:

  • 800 μg Vitamin A
  • 600 IU Vitamin D
  • 10 mg Vitamin E
  • 70 mg Vitamin C
  • 1.4 mg Thiamine
  • 1.4 mg Riboflavin
  • 18 mg Niacin
  • 1.9 mg Vitamin B6
  • 2.6 μg Vitamin B12
  • 2800 μg Folic Acid
  • 60 mg Iron
  • 15 mg Zinc
  • 2 mg Copper
  • 65 μg Selenium
  • 150 μg Iodine
Active Comparator: Iron and Folic Acid - 2

The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Iron and folic acid groups 1 and 2 receive: iron (60mg) and folic acid (2800μg), based on current WHO recommendations for WRA.

The doses of weekly and daily iron (60mg) and folic acid (2800μg) are based on current WHO recommendations for WRA.

Placebo Comparator: Folic Acid - 2

The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period.

It is unethical to have a placebo group as FA is universally recommended for WRA to prevent neural tube defects. Therefore, the control group will receive 2800 μg FA once a week during the pre-pregnancy period. This dosage is safe and meets the minimum recommended intake of 400 μg/d for Women of Reproductive Age (WRA). Recent studies have shown that a weekly dose of 2800 μg FA is as effective as a daily dose of 400 μg in improving folic acid and reducing homocysteine levels among WRA.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Birth Size - Weight
Time Frame: At birth

Infant weight is measured as early as possible within 24 hours after birth using standard procedures. All measurements are obtained in duplicate by the same data collector. Weight is measured in grams (g).

At birth
Birth Size - Body Length
Time Frame: At birth

Infant length is measured as early as possible within 24 hours after birth using standard procedures. All measurements are obtained in duplicate by the same data collector. Length is measured in millimeters (mm).

At birth
Birth Size - Head Circumference
Time Frame: At birth

Infant head circumference is measured as early as possible within 24 hours after birth using standard procedures. All measurements are obtained in duplicate by the same data collector. Head circumference is measured in millimeters (mm).

At birth
Gestational Age
Time Frame: At birth

Gestational age is calculated based on the date of last menstrual period. This method has been shown to be reliable in previous work and the researchers expect precise estimates since women will be visited weekly from baseline during the pre-pregnancy period. Women who have delivered babies in the past 6 months are excluded.

At birth
Child length
Time Frame: From Birth to 24 months

Child length, measured in millimeters (mm) is measured at birth, 1, 3, 6, 9, 12, 15, 18, and 24 months of age.

From Birth to 24 months
Child weight
Time Frame: From birth through 24 months of age

Child weight, measured in grams (g), is measured at birth, 1, 3, 6, 9, 12, 15, 18, and 24 months of age.

From birth through 24 months of age
Bayley Scales of Infant and Toddler Development - Third Edition (Bayley-III) Score
Time Frame: 12 and 24 months

Child development is measured using the Bayley Scales of Infant and Toddler Development - Third Edition at 12 and 24 months of age. The Bayley-III is a standardized comprehensive assessment tool for assessing child development in children one month to 42 months old. The highest possible scaled score on each subtest is 19, and the lowest possible score is 1. Scores from 8 to 12 are considered average. Index scores for motor and language domains are derived from sums of the subtest scaled scores. Index scores range from 40-160 with higher scores indicating. Composite scores are calculated for the cognitive, language, and motor scales to compare children to a normative age-matched sample. Composite scores have a mean of 100 with a standard deviation of 15. Composite scores below 85 indicate mild cognitive impairment and scores below 70 indicate moderate to severe cognitive impairment.

12 and 24 months
Wechsler Intelligence Scale for Children - Fourth Edition (WISC-IV) Score
Time Frame: 6 to 7 years of age, 10 to 11 years of age

Child development is measured using the WISC-IV. This test has been validated and adapted in the Vietnamese context and takes 60-70 minutes to administer. The WISC-IV consists of 10 subtests (Vocabulary, Similarities, Comprehension, Block Design, Picture Concepts, Matrix Reasoning, Digit Span, Letter-Number Sequencing, Coding, and Symbol search). These are summed into four indices: the Verbal Comprehension Index (VCI, a measure of crystallized abilities), Perceptual Reasoning Index (PRI, a measure of inductive and quantitative reasoning), Working Memory Index (WMI, a measure of children's ability to memorize new information), Processing Speed Index (PSI, a measure of the speed of information processing including the ability to focus attention and quickly scan, discriminate and sequentially order visual information). The Full-Scale intelligence quotient (IQ) score ranges from 40 to 160 points with higher scores indicating higher intelligence. Scores of 90 to 109 are considered average.

6 to 7 years of age, 10 to 11 years of age
Weight-for-age Z score (WAZ)
Time Frame: 6 to 7 years of age, 10 to 11 years of age

The weight-for-age Z score (WAZ) is assessed in offspring of women receiving only FA, offspring of women who receive weekly pre-pregnancy IFA, and offspring of women who receive weekly MM supplements.

6 to 7 years of age, 10 to 11 years of age
Height-for-Age Z Score (HAZ)
Time Frame: 6 to 7 years of age, 10 to 11 years of age

The height-for-age Z score (HAZ) is assessed in offspring of women receiving only FA, offspring of women who receive weekly pre-pregnancy IFA, and offspring of women who receive weekly MM supplements.

6 to 7 years of age, 10 to 11 years of age
Weight-for-Height Z Score (WHZ)
Time Frame: 6 to 7 years of age

The weight-for-height Z score (WHZ) is assessed in offspring of women receiving only FA, offspring of women who receive weekly pre-pregnancy IFA, and offspring of women who receive weekly MM supplements.

6 to 7 years of age
Body Mass Index Z Score (BMI-Z)
Time Frame: 10 to 11 years of age

The body mass index Z Score (BMI-Z) is assessed in offspring of women receiving only FA, offspring of women who receive weekly pre-pregnancy IFA, and offspring of women who receive weekly MM supplements.

10 to 11 years of age
Body composition (Lean mass/fat free mass index)
Time Frame: 6 to 7 years of age, 10 to 11 years of age

Body composition (Lean mass/fat free mass index) in offspring of women receiving only FA, offspring of women who receive weekly pre-pregnancy IFA, and offspring of women who receive weekly MM supplements

6 to 7 years of age, 10 to 11 years of age

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mothers' iron status
Time Frame: At baseline, 1 month postpartum, 3 months postpartum

Venous blood samples (5 ml) will be collected from women at: baseline, the first prenatal visit and at 1 and 3 months post partum. Anemia will be defined as Hb value <12 g/L for non-pregnant women, and <11g/L for pregnant women and infants, and iron deficiency as serum ferritin <12 μg/L (93).

At baseline, 1 month postpartum, 3 months postpartum
Infants' iron status
Time Frame: Birth, 3 months of age

Infant iron status is measured in cord blood samples (5 ml) obtained at delivery and at 3 months of age using a capillary blood sample that is obtained from a heel prick. The hemoglobin concentration are measured from a drop of blood using the HEMOCUE B- Hb photometer. The blood samples are then centrifuged and serum samples are aliquoted into microcuvettes and handled in the same way as described for mothers. Serum ferritin and transferrin receptor concentrations will be assayed using the ELISA method.

Birth, 3 months of age
Center for Epidemiological Studies Depression Scale (CES-D) Score
Time Frame: At baseline, during pregnancy, 3 months postpartum

Maternal depression is assessed with the Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report instrument asking respondents if they have experienced symptoms of depression during the past week. Responses are given on a scale of 0 to 3 where rarely is scored as 0 and most of the time is scored as 3. Total scores range from 0 to 60 and higher scores indicate greater symptoms of depression.

At baseline, during pregnancy, 3 months postpartum
Edinburgh Postnatal Depression Scale (EPDS) Score
Time Frame: At baseline, during pregnancy, 3 months postpartum

Maternal depression is assessed with the Edinburgh Postnatal Depression Scale (EPDS). The EPDS includes 10-items asking participants about symptoms of depression that they have experienced in the past 7 days. Responses are given on a 4-point scale where 0 corresponds with the least amount of symptoms and 3 corresponds with the highest amount of symptoms. Total scores range from 0 to 30 with higher scores indicating increased symptoms of depression. Scores of 10 and greater indicate possible depression.

At baseline, during pregnancy, 3 months postpartum

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Academic Achievement
Time Frame: 10 to 11 years of age

Academic achievement is evaluated with an assessment tool that has been used previously in Vietnam as part of the Young Lives Study. Study participants will take assessments in mathematics and Vietnamese (reading) at the beginning of the academic year when they enter Grade 5 in the school setting. Each test will take approximately 45 minutes. The test instruments in both math and reading employ a 30-item multiple-choice format and were developed in consultation with curriculum experts from the Vietnamese National Institute of Educational Sciences and are in line with those employed in the Ministry of Education & Training (MOET)/World Bank Grade 5 Study to measure learning levels in relation to curricular expectations, covering key subject domains at a range of levels of cognitive demand.

10 to 11 years of age

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Usha Ramakrishnan, PhD, Emory University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2011

Primary Completion (Actual)

September 1, 2014

Study Completion (Actual)

August 1, 2023

Study Registration Dates

First Submitted

August 13, 2012

First Submitted That Met QC Criteria

August 14, 2012

First Posted (Estimated)

August 15, 2012

Study Record Updates

Last Update Posted (Actual)

October 2, 2026

Last Update Submitted That Met QC Criteria

September 30, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.